

# 1 **Unequal access to diagnosis of myalgic encephalomyelitis in England**

2

3 Gemma L. Samms<sup>1</sup> and Chris P. Ponting<sup>1\*</sup>

4 \* Corresponding Author

5 <sup>1</sup> MRC Human Genetics Unit, The University of Edinburgh, Edinburgh, Scotland, EH4 2XU, UK

6

## 7 **Abstract**

### 8 **Background**

9 People with Myalgic Encephalomyelitis (ME/CFS; sometimes referred to as chronic fatigue  
10 syndrome) experience very poor health-related quality of life and only rarely recover. ME/CFS has  
11 no curative treatment and no single diagnostic test. Public health and policy decisions relevant to  
12 ME/CFS require knowledge of its prevalence and barriers to diagnosis. However, people with  
13 ME/CFS report lengthy diagnostic delays and widespread misunderstanding of their symptoms.  
14 Published prevalence estimates vary greatly by country, gender, age and ethnicity.

### 15 **Methods**

16 Hospital Episode Statistics data is routinely collected by the NHS in England together with patient  
17 age, gender and ethnicity. This data, downloaded from the Feasibility Self-Service of NHS DigiTrials,  
18 was used to stratify individuals with the ICD-10 code that best reflects ME/CFS symptoms (G93.3;  
19 “Postviral fatigue syndrome”) according to their age, self-reported gender and ethnicity, General  
20 Practice and NHS England Integrated Care Board (ICB).

### 21 **Results**

22 In all, 100,055 people in England had been diagnosed with ME/CFS (ICD-10:G93.3) between April 1  
23 1989 and October 7 2023, 0.16% of all registered patients. Of these, 79,445 were females and  
24 20,590 males, a female-to-male ratio of 3.88:1. Female relative to male prevalence peaked at about  
25 6-to-1 in individuals’ fourth and fifth decades of life. Prevalence varied widely across the 42 ICBS:  
26 0.086%-0.82% for females and 0.024%-0.21% for males. White individuals were approximately 5-fold

27 more likely to be diagnosed with ME/CFS than others; black, Asian or Chinese ethnicities are  
28 associated with particularly low rates of ME/CFS diagnoses. This ethnicity bias is stronger than for  
29 other common diseases. Among active English GP practices, 176 (3%) had no registered ME/CFS  
30 patients. Eight ICBs (19%) each contained fewer than 8 other-than-white individuals with a G93.3  
31 code despite their registers containing a total of 293,770 other-than-white patients.

## 32 **Conclusion**

33 Those who are disproportionately undiagnosed with ME/CFS are other-than-white ethnic groups,  
34 older females (>60y), older males (>80y), and people living in areas of multiple deprivation. The  
35 lifetime prevalence of ME/CFS for English females and males may be as high as 0.92% and 0.25%,  
36 respectively, or approximately 390,000 UK individuals overall. This improved estimate of ME/CFS  
37 prevalence allows more accurate assessment of the socioeconomic and disease burden imposed by  
38 ME/CFS.

39

## 40 **Introduction.**

41

42 At the population scale, estimates of disease morbidity and prevalence inform public health and  
43 policy decisions; for individuals, accurate diagnosis informs symptom management and treatment.  
44 Myalgic Encephalomyelitis (ME; sometimes referred to as Chronic Fatigue Syndrome [1]) is a chronic  
45 multi-system disorder resulting in very poor health-related quality of life and from which patients  
46 only rarely recover [2][3]. ME/CFS is relatively common [4]: prevalence estimates in the UK or the  
47 USA range from 0.2%-0.4% [5][6][7], depending on case definition. A meta-analysis of 56 data sets  
48 covering 1.1m individuals indicated an even higher prevalence, at 0.89% (95% CI: 0.60-1.33).  
49 However, this study's criteria did not require post-exertional malaise (PEM), the worsening or new  
50 appearance of symptoms after previously tolerated physical or cognitive exertion, which  
51 nevertheless is a primary symptom of ME/CFS [8]. More recently, the USA National Health Interview

52 Survey reported 1.3% of adults having a ME/CFS diagnosis and ongoing symptoms during 2021-2022  
53 [9], and the All of Us study report 0.46% of their USA cohort with ME/CFS (ICD9CM-780.71; [10]).

54

55 ME/CFS diagnosis varies firstly by sex, with women diagnosed two- to five-times more often than  
56 men and also tending to report more severe symptoms [11][9]. Diagnosis also may vary by ethnicity,  
57 although studies disagree on which group is more frequently diagnosed: African Americans and  
58 Native Americans [12], or White or Black (non-Hispanic) individuals [9], or African American and  
59 Latinx youth [13][7].

60

61 In this study, we report Hospital Episode Statistics (HES) data for NHS Hospitals in England,  
62 specifically the ICD-10 code G93.3 (“Postviral fatigue syndrome”) which is the code that best reflects  
63 ME/CFS symptoms. Rather than being General Practice (GP) data, and rather than being UK-wide,  
64 the data is HES- and England-specific, and hence does not report UK-wide prevalence. Nevertheless,  
65 when stratified by age, self-reported ethnicity and sex the data reveals substantial population  
66 variation in ME/CFS diagnosis.

67

## 68 **Results**

69

### 70 *Prevalence by age, deprivation and sex*

71 On 7 October 2023, 100,055 people had an electronic health record code for ME/CFS across the 42  
72 NHS England Integrated Care Boards (ICBs). These are among 62,782,175 people (0.16%) with a valid  
73 NHS number, who were registered with a GP and were not deceased. This information was supplied  
74 by the Feasibility Self-Service of NHS DigiTrials [14] who provide Hospital Episode Statistics that are  
75 routinely collected by the NHS in England and held by NHS England. In all, 79,445 (0.25% of  
76 31,297,675) females and 20,590 (0.065% of 31,481,510) males were associated with the ICD10 G93.3

77 code, a female-to-male (F/M) ratio of 3.88:1; 20 people with ME/CFS did not specify their gender.  
78 F/M ratio exceeded 3.3 across all of the 42 ICBS (range 3.3-4.5) (**Figure 1A**).

79

80 Across the ICBS, female or male prevalence varied by an order of magnitude: 0.086%-0.82% and  
81 0.024%-0.21%, respectively. Cornwall and the Isles of Scilly had the highest prevalence for each  
82 gender, and North West or North East London the lowest for females or males, respectively (**Figure**  
83 **1B**).

84

85 Point prevalence of ME/CFS varied greatly across lifespan, peaking at about 50 years of age for  
86 females and over a decade later for males (**Figure 2A**). In individuals' fourth and fifth decades the  
87 F/M ratio peaked at an exceptionally large value, approximately 6-to-1.

88

89 ME/CFS prevalence varied 1.5-fold by deprivation assessed by the Index of Multiple Deprivation  
90 (IMD). The IMD is a measure of relative deprivation for small areas in England [15] combining seven  
91 domains: income; employment; education, skills and training; health and disability; crime; housing  
92 and services; and the living environment. Each small area has been ranked and divided into tenths  
93 ('deciles') from the most deprived (decile 1) to the least deprived (decile 10). ME/CFS prevalence  
94 was lowest for those living in areas among the three most deprived deciles (**Figure 2B**).

95

#### 96 *Prevalence by ethnicity*

97 Ethnic groups showed unexpectedly large variation in ME/CFS prevalence. Specifically, white  
98 prevalence was 4.9-fold higher than other-than-white prevalence (0.24% vs 0.049%, respectively).

99 This finding was observed across all ICBS for both sexes (**Figure 1B**). Variation of ME/CFS prevalence  
100 by IMD deciles was similar between white and other-than-white ethnicities (**Figure 2C**).

101

102 ME/CFS prevalence of other-than-white British individuals was between one-tenth and one-third  
103 that for white British. Those with Chinese, Asian/Asian British or black/black British ethnicity were  
104 11%, 11%-19%, or 10%-35%, respectively, less likely to be diagnosed with ME/CFS (**Figure 3A**). The  
105 low prevalence of ME/CFS for other-than-white ethnicity categories is more profound than for other  
106 diseases, for example fibromyalgia and clinical depression (**Figure 3A**).

107

108 Eight ICBs each contained fewer than 8 other-than-white individuals with a G93.3 code ( $\leq 0.0027\%$   
109 for 293,770 other-than-white individuals). These 8 ICBs were Dorset; Gloucestershire; Herefordshire  
110 and Worcestershire; Lincolnshire; Northamptonshire; Shropshire, Telford and Wrekin; Somerset;  
111 and, Staffordshire and Stoke-on-Trent.

112

113 In summary, ME/CFS diagnosis in England is highest among older, white females, and lowest among  
114 younger other-than-white males; the variation is 50-fold between these three categories (**Figure 3B**).

115

#### 116 *Prevalence per GP practice*

117 Lastly, we considered 6,113 English GP practices with at least 2,500 registered patients which each,  
118 given the national prevalence of 0.16% (above), would be expected to have 4 or more ME/CFS  
119 patients registered. Two-thirds of these practices (4,061; 66%) had 8 or more registered patients  
120 with ME/CFS and 97% (5,937) reported at least one individual with ME/CFS. Of the remaining  
121 practices, 176 (3%) had no registered ME/CFS patients recorded in HES despite being operational  
122 and having a median of 4,765 registered patients (range 2,665-12,170), a total population of  
123 917,570. These 176 practices are disproportionately located in the most deprived areas of England  
124 (**Figure 4**).

125

126 **Discussion**

127 Across England, ME/CFS diagnosis varies 50-fold, with considerable variation by gender, age,  
128 ethnicity, and location (**Figure 3B**; **Figure 1**; **Figure 2C**). Female-bias contributes about 4-fold, mid-  
129 way among previous values for single-country or international ME/CFS cohorts (1.5-6 fold  
130 [11][1][16][17][18][19][20]). This wide variation may result, in part, from cohorts sampling from  
131 different age ranges (**Figure 2A**). Young (<40y) or old (>40y) age contributes ~3-fold to ME/CFS  
132 prevalence variation (**Figure 2A**; **Figure 3B**), reflecting an accumulation of ME/CFS diagnoses over  
133 adult life. Decreased ME/CFS female prevalence in later life (>60y; **Figure 1B**) cannot be due to  
134 recovery, as records are deleted only rarely, or increased mortality [21] but could reflect historically  
135 low levels of diagnoses. The 20y difference between the highest male (ages 71-80y) and highest  
136 female (ages 51-60y) prevalence is puzzling although it may reflect gender-specific historical  
137 variation in ME/CFS diagnosis. Older females (>60y) and males (>80y) are less likely to be coded with  
138 ME/CFS in their hospital records (**Figure 2A**). However, note that if they were diagnosed before 1st  
139 April 1989 and were not since re-coded in their hospital records, their diagnosis will be missing from  
140 the data we analysed.

141 White versus other-than-white ethnicity accounts for a further ~5-fold variation (**Figure 3B**), with  
142 some ethnicities (e.g. black, Asian or Chinese ancestry) associated with particularly low rates of  
143 ME/CFS diagnoses (**Figure 3A**). This ethnicity bias is stronger than for other common diseases such  
144 as dementia, ischaemic heart disease, clinical depression, and fibromyalgia [22](**Figure 3A**). The bias  
145 is unlikely to reflect genetic differences [23], or to unequal access to primary care because other-  
146 than-white individuals are not less likely to visit GP services [24]. Rather it is likely due to fewer  
147 hospital visits by people of East Asian ancestry [24] and to wider social and economical health  
148 factors [25]. Barriers to diagnosing and managing ME/CFS in other-than-white groups have  
149 previously been recognised [26]. These will need to be overcome if there is to be equitable access to  
150 ME/CFS diagnosis and healthcare.

151 Age-at-ME/CFS diagnosis is highly variable, especially for paediatric ME/CFS cases: this study  
152 identified few <18y old ME/CFS cases in England (0.010% for both genders combined; **Figure 2A**),  
153 consistent with the UK overall [11]. In other countries, however, paediatric prevalence of ME/CFS is  
154 much higher [27], e.g., 0.75% in a USA community cohort [13]; 26% of Norwegian ME/CFS patients  
155 were younger than 20y old [17]. Paediatric ME/CFS referral services in England and the rest of the  
156 UK are limited [28].

157 A strength of this study is that it captures all ME/CFS diagnoses given the G93.3 ICD-10 code during  
158 admissions, outpatient appointments and historical Accident and Emergency attendances at English  
159 NHS hospitals up to October 2023. It is over two orders of magnitude larger in scale than a primary  
160 care study of 3 English areas [5] whose prevalence estimate (0.11-0.20%) is comparable to this  
161 study's G93.3 prevalence (0.16%). A weakness is that those whose ME/CFS was diagnosed in primary  
162 care will only have been included if their G93.3 code was subsequently added to the HES data in  
163 secondary care.

164 With this study's data, we can now estimate the number of people in the UK who would have a  
165 ME/CFS diagnosis (i.e. the G93.3 code) if there were minimal social and healthcare barriers to  
166 diagnosis. For this, we used the maximal ME/CFS prevalences for white females and males (0.92%  
167 and 0.25%, respectively), which are for NHS Cornwall and Isles of Scilly (**Figure 1B**). This ICB would be  
168 expected to have the highest fraction of diagnosed ME/CFS patients as it has the oldest population  
169 (average ~45y [females] and ~44y [males]), the highest F/M ratio (1.04) and, most strikingly, the  
170 lowest other-than-white population (2.0%). If all 67 million UK citizens [29] were to have a lifetime  
171 prevalence matching the point prevalence of NHS Cornwall and Isles of Scilly then 83,750 males and  
172 308,200 females would be given a G93.3 ME/CFS diagnosis in their lifetime. These are lower bound  
173 estimates because no account is taken of those in NHS Cornwall and Isles of Scilly who have yet to  
174 receive a ME/CFS diagnosis. This total of 391,950 would be a 57% increase over a current prevalence  
175 estimate of 250,000 [30]. Even if half of these do not meet more stringent diagnostic criteria for

176 ME/CFS (as previously [31][32]), then this reduction could be offset by those diagnosed in primary  
177 care, but not coded in the HES data analysed in this study. In summary, we suggest that the 2023 UK  
178 lifetime prevalence of ME/CFS diagnosed using stringent criteria is approximately 300,000 for  
179 females and 85,000 for males (i.e., 0.92% and 0.25%, respectively).

180 In summary, these results reveal deficiencies in ME/CFS diagnosis across different groups in England.  
181 To address these deficiencies, improved training of medical professionals should be available [33]  
182 and research into identifying accurate diagnostic tests should be prioritised. Even when diagnosed,  
183 there is no curative therapy for ME/CFS, only symptom management [33] Nevertheless, an  
184 individual's ME/CFS diagnosis provides considerable value as it: (i) counters the delegitimization of  
185 problems often experienced by ME/CFS patients [34][35], (ii) improves patient/professional  
186 relationships, (iii) facilitates symptom management, (iv) enables application for disability benefits,  
187 (v) assists recruitment to future clinical trials of potentially effective treatments, and (vi) helps  
188 individuals to join supportive and informative patient communities.

189

## 190 **Methods**

191 The NHS DigiTrials Feasibility Self-Service (England only [14]) returned all ME/CFS diagnoses since 1<sup>st</sup>  
192 April 1989, stratified by ICB, sex, age and self-reported ethnicity (accessed on 7-10 October 2023).  
193 For each stratum, NHS DigiTrials data is rounded: counts equal to or exceeding 8 are rounded to the  
194 nearest increment of 5; counts equal to or less than 7 were not provided and so were set to zero.  
195 Data was for 62,782,175 individuals who are alive, have a valid NHS number and are registered with  
196 a GP in England. Data also includes those who previously met these criteria but are no longer  
197 residing in England [36]. Individuals are recorded once without duplicates. NHS DigiTrials returns  
198 data derived from Hospital Episode Statistics (HES) for admissions, outpatient appointments and  
199 historical Accident and Emergency attendances [36]. HES are linked via the patients' registered GP  
200 practice, and these 6,119 GP practices are linked to 42 ICBs. 6 GP practices were not considered



201 further because they had fewer than 2,500 registered patients. HES data is updated monthly, on the  
202 second day of each month. Personal demographic data is updated daily. Patients with multiple  
203 diagnoses of the same type/code are counted only once, specifically the latest occurrence. As in  
204 other studies (e.g., [17]) we consider G93.3 to be the ICD-10 code that best reflects ME/CFS  
205 symptoms.

206

207 We apply the UK Government's recommendations for describing ethnicity [37]. NHS DigiTrials uses  
208 self-reported ethnicity as classified in the 2001 census. 'White' includes 'white British', 'white Irish'  
209 and 'Any other white background'. 'Other than white' includes any other ethnic group; Asian or  
210 Asian British - Any other Asian background; Asian or Asian British - Bangladeshi; Asian or Asian  
211 British - Indian; Asian or Asian British - Pakistani; Black or Black British - African; Black or Black British  
212 - Any other Black background; Black or Black British - Caribbean; Chinese; Mixed - Any other mixed  
213 background; Mixed - White & Asian; Mixed - White & Black African; Mixed - White & Black  
214 Caribbean). These two categories exclude those whose ancestry is ambiguous (i.e. 'not stated' or  
215 'unknown'). Individuals whose ethnicity was 'not stated' or 'unknown' were included for non-  
216 ethnicity related analyses.

217

218 NHS DigiTrials provided numbers of ME/CFS patients coded with G93.3 in active GP practices in  
219 England. For each GP practice these were indicated as between 1 and 7, or if equal to or above 8,  
220 provided to the nearest increment of 5. Active practices were those without a closed date, with  
221  $\geq 2,500$  registered patients, whose status is 'active' and 'operational' (similarly for its related ICB),  
222 and with a valid postcode.

223 For Figure 2B and 2C patients were partitioned into deciles of English indices of deprivation (IMD;  
224 2019) by their address (1=most deprived, 10=least deprived). For Figure 4, English indices of  
225 deprivation for GP practices were acquired using their postcodes [15].

226

227 **Acknowledgements**

228 NHS data is copyright © 2022, NHS England, re-used with the permission of NHS England. All rights  
229 reserved. Access to this data was provided by NHS DigiTrials and the Feasibility Self-Service. Funding  
230 for access was provided by the National Institute for Health and Care Research (NIHR) and Medical  
231 Research Council (MRC), grant number MC\_PC\_20005. GLS was funded by a PhD studentship from  
232 ME Research UK. We would like to thank Profs Sarah Wild and Raj Bhopal (University of Edinburgh)  
233 and Simon McGrath for helpful discussions, and Dr Diana Garcia (University of Edinburgh) for  
234 assistance in acquiring the NHS DigiTrials data.

235

236 **Figure Legends.**

237 **Figure 1. Diagnoses across 42 English Integrated Care Boards (ICB).** (A) Ratios of female-to-male  
238 ME/CFS diagnoses (ICD-10:G93.3 codes) by ICB. (B) Point prevalence of males (left) or females (right)  
239 with ME/CFS stratified by ethnicity: either white or other-than-white. Blue: white females; Orange:  
240 Other-than-white Females; Green: white Males; Purple: Other-than-white Males.

241

242 **Figure 2. ME/CFS diagnoses by age or deprivation.** (A) Ages of females or males with ME/CFS  
243 diagnoses in England (light blue: females; dark blue: males; black: overall ratio) as of 7<sup>th</sup> October  
244 2023. The female-to-male ME/CFS diagnosis ratios for every age decade are shown in boxes. (B)  
245 ME/CFS patients partitioned by Indices of multiple deprivation (IMD) in deciles. (C) As (B), but  
246 separated by self-reported white or other-than-white ethnicities.

247

248 **Figure 3. Relative prevalence of ME/CFS and other diseases stratified by ethnic group, age and**  
249 **gender.** (A) Prevalence of ME/CFS (ICD-10:G93.3), Fibromyalgia (ICD-10: M79.7), Rheumatoid  
250 arthritis (M05.3, M05.8, M05.9, M06.0, M06.8, M06.9 or M08.0), clinical depression (F32 or F33  
251 codes), Irritable Bowel Syndrome (K58.0 or K58.9), Coeliac Disease (K90.0), or Multiple Sclerosis  
252 (G35) for self-reported ethnicities relative to 'white British'. Codes were downloaded from NHS

253 DigiTrials on 8<sup>th</sup> October 2023. (B) ME/CFS prevalence for female or male groups, of younger or  
254 older age, and of white or other-than-white ethnicity, relative to young ( $\leq 40$  years old) white males  
255 (normalised to 1.0).

256

257 **Figure 4. English GP practices.** Numbers of active GP practices without registered ME/CFS patients  
258 recorded in HES stratified by indices of multiple deprivation.

259

## 260 **References**


- 261 1. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome;  
262 Board on the Health of Select Populations; Institute of Medicine. Beyond Myalgic  
263 Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. 2015.
- 264 2. Falk Hvidberg M, Brinth LS, Olesen A V, Petersen KD, Ehlers L. The Health-Related Quality of Life  
265 for Patients with Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS). PLoS One.  
266 2015;10:e0132421.
- 267 3. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome.  
268 Occup Med (Lond). 2005;55:20–31.
- 269 4. Valdez AR, Hancock EE, Adebayo S, Kiernicki DJ, Proskauer D, Attewell JR, et al. Estimating  
270 Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine  
271 Learning. Front Pediatr. 2018;6:412.
- 272 5. Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S, et al. Prevalence of myalgic  
273 encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-  
274 sectional study in primary care. BMC Med. 2011;9:91.
- 275 6. Reyes M, Nisenbaum R, Hoaglin DC, Unger ER, Emmons C, Randall B, et al. Prevalence and  
276 incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med. 2003;163:1530–6.
- 277 7. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys A V., Taylor RR, et al. A Community-  
278 Based Study of Chronic Fatigue Syndrome. JAMA Intern Med. 1999;159:2129–37.
- 279 8. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a  
280 comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study  
281 Group. Ann Intern Med. 1994;121:953–9.
- 282 9. Vahratian A, Lin J-MS, Bertolli J, Unger ER. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome  
283 in Adults: United States, 2021–2022. NCHS Data Brief No. 488. 2023.  
284 <https://www.cdc.gov/nchs/products/databriefs/db488.htm>. Accessed 31 Jan 2024.
- 285 10. All of Us Research Hub myalgic encephalomyelitis. 2024.  
286 <https://databrowser.researchallofus.org/ehr/conditions/myalgic%20encephalomyelitis>. Accessed 31  
287 Jan 2024.

- 288 11. Bretherick AD, McGrath SJ, Devereux-Cooke A, Leary S, Northwood E, Redshaw A, et al. Typing  
289 myalgic encephalomyelitis by infection at onset: A DecodeME study. *NIHR open research*. 2023;3:20.
- 290 12. Dinos S, Khoshaba B, Ashby D, White PD, Nazroo J, Wessely S, et al. A systematic review of  
291 chronic fatigue, its syndromes and ethnicity: prevalence, severity, co-morbidity and coping. *Int J*  
292 *Epidemiol*. 2009;38:1554–70.
- 293 13. Jason LA, Katz BZ, Sunnquist M, Torres C, Cotler J, Bhatia S. The Prevalence of Pediatric Myalgic  
294 Encephalomyelitis/Chronic Fatigue Syndrome in a Community-Based Sample. *Child Youth Care*  
295 *Forum*. 2020;49:563–79.
- 296 14. NHS DigiTrials. 2024. <https://digital.nhs.uk/services/nhs-digitrials>. Accessed 31 Jan 2024.
- 297 15. English indices of deprivation 2019. 2019. [https://www.gov.uk/government/statistics/english-](https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019)  
298 [indices-of-deprivation-2019](https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019). Accessed 31 Jan 2024.
- 299 16. Collin SM, Bakken IJ, Nazareth I, Crawley E, White PD. Trends in the incidence of chronic fatigue  
300 syndrome and fibromyalgia in the UK, 2001-2013: a Clinical Practice Research Datalink study. *J R Soc*  
301 *Med*. 2017;110:231–44.
- 302 17. Bakken IJ, Tveito K, Gunnes N, Ghaderi S, Stoltenberg C, Trogstad L, et al. Two age peaks in the  
303 incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study  
304 from Norway 2008-2012. *BMC Med*. 2014;12:167.
- 305 18. Knight S, Harvey A, Lubitz L, Rowe K, Reveley C, Veit F, et al. Paediatric chronic fatigue syndrome:  
306 complex presentations and protracted time to diagnosis. *J Paediatr Child Health*. 2013;49:919–24.
- 307 19. Orji N, Campbell JA, Wills K, Hensher M, Palmer AJ, Rogerson M, et al. Prevalence of myalgic  
308 encephalomyelitis/chronic fatigue syndrome (ME/CFS) in Australian primary care patients: only part  
309 of the story? *BMC Public Health*. 2022;22:1516.
- 310 20. Pheby D, Lacerda E, Nacul L, Drachler M de L, Champion P, Howe A, et al. A Disease Register for  
311 ME/CFS: Report of a Pilot Study. *BMC Res Notes*. 2011;4:139.
- 312 21. Roberts E, Wessely S, Chalder T, Chang C-K, Hotopf M. Mortality of people with chronic fatigue  
313 syndrome: a retrospective cohort study in England and Wales from the South London and Maudsley  
314 NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Clinical Record Interactive Search  
315 (CRIS) Register. *Lancet*. 2016;387:1638–43.
- 316 22. Mortality from leading causes of death by ethnic group, England and Wales: 2012 to 2019. 2021.  
317 [https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/article](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/mortalityfromleadingcausesofdeathbyethnicgroupenglandandwales/2012to2019)  
318 [s/mortalityfromleadingcausesofdeathbyethnicgroupenglandandwales/2012to2019](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/mortalityfromleadingcausesofdeathbyethnicgroupenglandandwales/2012to2019). Accessed 31 Jan  
319 2024.
- 320 23. Birney E, Inouye M, Raff J, Rutherford A, Scally A. The language of race, ethnicity, and ancestry in  
321 human genetic research. 2021.
- 322 24. Nazroo JY, Falaschetti E, Pierce M, Primatesta P. Ethnic inequalities in access to and outcomes of  
323 healthcare: analysis of the Health Survey for England. *J Epidemiol Community Health* (1978).  
324 2009;63:1022–7.
- 325 25. Chouhan K, Nazroo J. Health inequalities. In: Byrne B, Alexander C, Khan O, Nazroo J, Shankley W,  
326 editors. *Ethnicity, Race and Inequality in the UK*. Bristol: Bristol University Press; 2020. p. 73–92.


- 327 26. Bayliss K, Riste L, Fisher L, Wearden A, Peters S, Lovell K, et al. Diagnosis and management of  
328 chronic fatigue syndrome/myalgic encephalitis in black and minority ethnic people: a qualitative  
329 study. *Prim Health Care Res Dev.* 2014;15:143–55.
- 330 27. Lim E-J, Ahn Y-C, Jang E-S, Lee S-W, Lee S-H, Son C-G. Systematic review and meta-analysis of the  
331 prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). *J Transl Med.*  
332 2020;18:100.
- 333 28. Diagnosis of ME/CFS. The importance of having an early and accurate diagnosis. 2022.
- 334 29. Population estimates for the UK, England, Wales, Scotland and Northern Ireland: mid-2021.  
335 2022.  
336 <https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2021>. Accessed 31 Jan 2024.
- 338 30. National Institute for Health and Care Excellence. Myalgic encephalomyelitis (or  
339 encephalopathy)/chronic fatigue syndrome: diagnosis and management. 2021.
- 340 31. Newton JL, Mabillard H, Scott A, Hoad A, Spickett G. The Newcastle NHS Chronic Fatigue  
341 Syndrome Service: not all fatigue is the same. *J R Coll Physicians Edinb.* 2010;40:304–7.
- 342 32. Devasahayam A, Lawn T, Murphy M, White PD. Alternative diagnoses to chronic fatigue  
343 syndrome in referrals to a specialist service: service evaluation survey. *JRSM Short Rep.* 2012;3:4.
- 344 33. Muirhead N, Muirhead J, Lavery G, Marsh B. Medical School Education on Myalgic  
345 Encephalomyelitis. *Medicina (Kaunas).* 2021;57.
- 346 34. Froehlich L, Hattesoehl DB, Cotler J, Jason LA, Scheibenbogen C, Behrends U. Causal attributions  
347 and perceived stigma for myalgic encephalomyelitis/chronic fatigue syndrome. *J Health Psychol.*  
348 2022;27:2291–304.
- 349 35. Asbring P, Närvänen A-L. Women’s experiences of stigma in relation to chronic fatigue syndrome  
350 and fibromyalgia. *Qual Health Res.* 2002;12:148–60.
- 351 36. Hospital Episode Statistics (HES). 2023. <https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics>. Accessed 31 Jan 2024.
- 353 37. Writing about ethnicity. 2021. <https://www.ethnicity-facts-figures.service.gov.uk/style-guide/writing-about-ethnicity/>. Accessed 31 Jan 2024.
- 355
- 356

**Figure 1**




**A**




**B**



**Figure 2**



**Figure 3B**



**Figure 4**






Figure 3A

